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share the work provObjective: The efficacy of therapeutic vaccines against HIV-1 infection has been
modest. New inerts to redirect responses to vulnerable sites are urgently needed to
improve these results.
Design: We performed the first-in-human clinical trial with naked mRNA (iHIVARNA)
combining a dendritic cell activation strategy (TriMix:CD40LþCD70þcaTLR4 RNA)
with a novel HIV immunogen sequences (HTI immunogen).
Methods: A dose escalation, phase I clinical trial was performed in 21 chronic HIV-1-
infected patients under ARTwho received three intranodal doses ofmRNA (weeks 0, 2 and
4) as follow: TriMix-100g, TriMix-300g, TriMix-300g with HTI-300g, TriMix-300g with
HTI-600g, TriMix-300g with HTI-900g. Primary end-point was safety and secondary-
exploratory end-pointswere immunogenicity, changes in viral reservoir and transcriptome.
Results: Overall, the vaccine was secure and well tolerated. There were 31 grade 1/2
and 1 grade 3 adverse events, mostly unrelated to the vaccination. Patients who
received the highest dose showed a moderate increase in T-cell responses spanning
HTI sequence at week 8. In addition, the proportion of responders receiving any dose of
HTI increased from 31% at w0 to 80% postvaccination. The intervention had no impact
on caHIV-DNA levels, however, caHIV-RNA expression and usVL were transiently
increased at weeks 5 and 6 in the highest dose of iHIVARNA, and these changes were
positively correlated with HIV-1-specific-induced immune responses.
Conclusion: This phase I dose-escalating trial showed that iHIVARNA administration
was safe and well tolerated, induced moderate HIV-specific T-cell responses and
transiently increased different viral replication readouts. These data support further
exploration of iHIVARNA in a phase II study.
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2534 AIDS 2018, Vol 32 No 17IntroductionAntiretroviral therapy (ART) has proven to be highly
effective to prevent HIV-associated clinical progression
and death [1] and to influence the AIDS pandemic as part
of HIV prevention strategies [2,3]. Despite these
successes, current ART has a number of public health,
economical and clinical limitations. First, although 80%
of HIV-infected individuals in United States and Europe
know that they are HIV-infected, only 30 and 50%,
respectively, are virally suppressed (hence with low
probability of sexual transmission) [4,5]. Second, ART is
unable to cure or eradicate the infection [6]. The high
cost of lifelong treatment remains an important issue in
the implementation of the the Joint United Nations
Programme on HIV/AIDS (UNAIDS) strategy of
universal treatment. Third, suboptimal treatment adher-
ence can lead to the development of viral resistance [7].
Finally, the potential medium–long term adverse effects
of ART have important clinical limitations.
Awell tolerated, affordable and scalable cure could address
both the individual and public health limitations that are
associated with lifelong ART. The scientific community
has acknowledged this position and there is a growing
interest in developing curative strategies to tackle HIV
persistence [8,9], among, which therapeutic vaccines
represent one of the most promising approaches [10,11].
However, although, most immunogens have been able to
induce HIV-specific immune responses in clinical trials,
they have shown very limited efficacy to control viral
replication [12]. The cytolytic T-lymphocyte (CTL)
escape mutations and a poor antigen presentation by
dendritic cells are some of the major hurdles that need to
be addressed by rationally designed therapeutic vaccine
candidates to improve their effectiveness. New inserts to
redirect responses to vulnerable sites of HIV and vectors
targeting dendritic-cell pathways could be necessary to
achieve remission of HIV-1 infection [13].
Recently, direct administration of mRNA targeting
dendritic cells has been proposed as an alternative to the
classic immunogens [14–19]. Van Lint et al. [20] have
designed mRNAs encoding a mixture of activation
molecules functional in antigen-presenting cells (APC),
including CD40L, a constitutively active variant of Toll-
like receptor (TLR) 4 and CD70 (jointly referred as
TriMix). The intention behind this strategy is to induce
dendritic-cell maturation with CD40L and caTLR4 and
to support activated T-cell survival and proliferation with
CD70. dendritic cells modified in vitro or in vivo with
TriMix mRNA have been shown to be significantly more
potent and immunogenic than unmodified dendritic cell
[20,21]. Complementing these advances in vector design,
Mothe et al. [13] proposed a rational design for the
selection of HIV antigens based on the viral targets of
protective HIV-1 specific T-cell responses observed in
three large cohorts of HIV-infected individuals [13]. Thisapproach resulted in the design of the HIVACAT T-cell
Immunogen (HTI) sequence constituting 16 joined
fragments of 10–70 amino acids each, encoding critical
HIV-1 target epitopes in Gag, Pol, Vif and Nef. These
particular HIV-1 regions are more conserved and elicited
responses of higher functional avidity and broader cross-
reactivity than other segments in the HIV proteome [22].
Mice immunized with mRNA-encoding HTI in combi-
nation with TriMix [21] and mice and rhesus macaques
immunizedwithDNA/MVAexpressingHTI [22] showed
broad and balanced T-cell responses to several segments
within Gag, Pol, and Vif. These data demonstrate that it is
possible to redirect responses to vulnerable sites of HIV-1
while avoiding the induction of responses to potential
decoy targets that may divert effective T-cell responses
towards variable and less protective viral determinants.
We have performed the first-in-human phase I dose-
escalating clinical trial with naked mRNA containing
dendritic cell activation signals (TriMix) and encoding a
novel HIV immunogen sequence (HTI) to redirect T-cell
immunity inHIV-infected individuals to themost vulnerable
viral targets. The primary endpoint of this study included
feasibility and safety of the immune intervention, while the
secondary exploratory endpoints were immunogenicity,
changes in theviral reservoir and in transcriptomicvariations.Patients and methods
Patients and samples
From June 2015 until October 2016 in Barcelona, we
conducted a single-center, open-label, dose-escalating
phase I clinical trial in 21 chronic HIV-1 infected patients
under stable ART with plasma viral load (pVL) below
50 copies/ml and stable CD4þ T-cell counts above
450 cells/ml. Patients received three inguinal intranodal
doses of mRNA by ultrasound-guided injections per-
formed by a radiologist at weeks 0, 2 and 4 according to
the following dose escalation scheme (see Fig. 1a and b):
Group 1 (control): three patients received 100mg of
mRNA (i.e. 100mg TriMix mRNA).
Group 2 (control): three patients received 300mg of
mRNA (i.e. 300mg TriMix mRNA).
Group 3 (study): three patients received 600mg of
mRNA (i.e. 300mg HTI mRNA and 300mg TriMix
mRNA).
In these three groups, if two or more of the three patients
would have developed a dose-limiting toxicity (DLT),
Data and Safety Monitoring Board (DSMB) would have
been consulted and study could potentially have been
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Fig. 1. (a) Dose escalation flow chart. (b) Assignation of cohorts. DSMB, Data and Safety Monitoring Board; DLT, dose-limiting
toxicity.
2536 AIDS 2018, Vol 32 No 17terminated. If one or no patients would have had a DLT,
three patients would be enrolled at the next dose level.
Group 4 (study): three patients received 900mg of
mRNA (i.e. 600mg HTI mRNA and 300mg TriMix
mRNA). If two or more of the three first patients would
have shown DLT, then three additional patients would
have been enrolled at the previous dose level (600mg of
mRNA per vaccination). If one or no patients would
have had a DLT, three additional patients would have
been enrolled at the 900mg of mRNA dose level. If two
or more of the six patients receiving 900mg of mRNA
would have had a DLT, then three additional patients
would have been enrolled at the previous level dose
(600mg of mRNA per vaccination). If one or no patients
of the six patients would have had a DLT, six patients
would be enrolled at the next dose level.
Group 5 (study): six patients received 1200mg of mRNA
(i.e. 900mg HTI mRNA and 300mg TriMix mRNA).
Within each group, each patient was observed for a
minimum of 1 week before the next patient was treated.
All patients within a group were observed for a minimum
of 2 weeks after the third vaccination prior to
administration of the vaccine to a patient at the next
dose level (Fig. 1b). Patients could not change groups
or dose assignments upon the initiation of the study
protocol. The study treatment period was 4 weeks for
each patient. All the patients were followed-up for
24 weeks (see supplementary M&M, http://links.lww.
com/QAD/B364).
Immunogenicity evaluations
ELISPOT
Immunogenicity was assessed on cryopreserved periph-
eral blood mononuclear cells (PBMC) at baseline (i.e. day
of first immunization) and weeks 4, 6, 8 and 24 of follow-
up by the quantification of T-cell responses by a IFN-g
ELISPOT assay according to standardized operating
procedures (SOP) in a single research laboratory. Briefly,
cryopreserved PBMC were thawed and rested for
overnight at 37 8C. Next, 100 000 PBMCs were
stimulated with peptide pools (1mg of each single
peptide) in 100ml of complete media (Roswell Park
Memorial Institute with 10% fetal calf serum) in duplicate
conditions. To evaluate the HIV-specific T-cell responses
against the whole HIV proteome, we used sets of
overlapping HIV peptide pools [10 different pools
containing from 5 to 22 15-mer peptides, overlapping
by 11-mer, which matched the HTI immunogen (’IN’)
and 8 pools ranging from 62 to 105 15-mer peptides
covering NIH consB HIV sequences not located within
HTI (’OUT’ pools)]. Media alone in triplicate was used as
negative control. Phytohemagglutinin PHA-P (1mg/ml)
and stimulation with CEF (cytomegalovirus, Epstein–
Barr virus, and Flu) pool were used as positive controls.
Results are expressed as the mean number of spot-forming cells (SFC)/106 cells from duplicate wells. The
following criteria were used to define the technical
validity and positive responses: PBMC viability had to be
greater than 80% to be analyzed; the assay background
(PBMCs with media alone) had to be less than 50 SFC/
106 PBMC; positive responses against PHA-P had to be
above 500 SFC/106 PBMC; and ELISPOT responses
were considered positive in case of greater than 50 SFC/
106 PBMC and number of SFC/106 PBMC at least two-
fold over media control (Fig. 2).
Flow cytometry assays
We evaluated the activation (or senescence) of T (CD4þ
and CD8), B (CD19þ), natural killer cells (CD56þ), and
monocytes (CD14þ) according to the expression of
specific surface markers by flow cytometry (see Supple-
mentary Table S1, http://links.lww.com/QAD/B364).
Viral reservoir and ultrasensitive plasma viral
load assessment
To explore potential changes induced by the activation of
HIV-1-specific latently infected CD4þ T cells, proviral
HIV-DNA levels and cell-associated HIV-RNA expres-
sion were quantified at baseline and at weeks 4, 6, 8, and
24 of follow-up in peripheral CD4þ T cells. Additional
determinations of caHIV-RNA at week 2 þ1 day,
week 3, week 4 þ1 day, and week 5 were performed in
groups 4 and 5.
Both the parameters were measured by digital droplet
PCR (dd PCR) with two different sets of primers (50
LTR and Gag loci) to avoid mismatching as previously
described [23,24]. caHIV-RNA was calculated as HIV
RNA copies relative to the housekeeping gene TATA-
binding protein (TBP). Proviral HIV-DNA is expressed
as copies of HIV-DNA per million of CD4þ T cells
measured by the housekeeping gene RPP30.
In addition, the effect of vaccination on plasma viral load
(pVL) at baseline and week 2 þ 1 day, week 3, week 4,
week 4þ 1 day, week 5, week 6, week 8, and week 24 was
assessed in groups 4 and 5. In short, 5ml of EDTA plasma
was ultracentrifuged at 170 000 g for 1 h at 4 8C. Tubes
were equilibrated with Tris-buffered saline (50mM Tris-
Cl, pH 7.6; 150mmol/l NaCl) to a final volume of 12ml.
After centrifugation, 11.20ml of supernatant was
carefully aspirated and discarded. The pellet was
thoroughly resuspended in the remaining 800ml and
tested for viral load with the Cobas HIV-1 test on the
Roche Cobas 4800 system. To account for the
concentration of the virus, the obtained result was
multiplied by a factor 0.16 (0.8/5).
Transcriptome profiling
Transcriptome profiles were obtained from whole blood
samples collected in Tempus blood RNA tubes (Thermo
Fisher Scientific, Waltham, Massachusetts, USA), at
baseline and week 6. RNA was isolated according to
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Fig. 2. pETheRNA mRNA vector.the manufacturer’s instructions and hybridized onto
Affymetrix Human GenomeU133 Plus 2.0 microarray
chips as previously described (http://dx.doi.org/
10.1016/j.vaccine.2015.04.047). Samples were quantile
normalized and summarized using median polish (i.e. the
RMA method). During quality control, we had to
remove a single sample as it had insufficient quality to be
normalized. Batch effect removal, differential gene
expression and gene set analysis were performed using
limma. Principal component analysis (PCA) showed
batch effects related to RNA processing and hybridiza-
tion, but these could be effectively removed using limma.
Gene set analysis was performed using limma and the
REACTOME curated database gene set definitions
[25,26].
Statistical analysis
The sample size is the minimum required to the study
objectives as stated on Guideline on Requirements
for First-in-man clinical trials for potential high-risk
medicinal products (EMEA/CHMP/SWP/28367/
2007). This was an exploratory study, and the safety
analysis were descriptive. The safety endpoints were
described and summarized by number and percentage of
adverse events and grading. We also stratified the adverse
events into related (possibly, probably and definitely
related to vaccination) and unrelated to vaccination
(unlikely to be related, unrelated). The total magnitude ofHIV-1 specific IFN-g T-cell responses was described as
the sum of SFC/million input PBMC. Differences in
breadth, magnitude of HIV-1 specific responses, caHIV-
DNA, caHIV-RNA or usVL between two longitudinal
determinations in the same individuals were assessed by
Wilcoxon Signed-Rank Test.Results
mRNA vaccination with TriMix or iHIVARNA in
chronically antiretroviral-treated HIV-1-infected
patients is well tolerated
All the 21 patients received the three doses of TriMix or
the different doses of iHIVARNA (HTI with TriMix)
given by inguinal intranodal route. All 21 participants
completed the study as per protocol and were included in
the safety analysis. Clinical characteristics of the patients
are shown in Table 1. Overall, the vaccine was safe and
well tolerated. No serious adverse events nor deaths were
observed. A total of 32 adverse events were reported
during follow-up (4, 7, 5, 11 and 5 in each group,
respectively). Nineteen adverse events were classified as
grade 1, twelve as grade 2 and one as grade 3. Half of them
(n¼ 16/32) were not related to vaccination, 14 had a
possible relationship and 2 had a definite relationship
(Table 2). No laboratory abnormalities were observed
during the follow-up.
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Table 1. Clinical characteristics of participants.
n¼21 Group 1 (n¼3) Group 2 (n¼3) Group 3 (n¼3) Group 4 (n¼6) Group 5 (n¼6)
Median age (IQR) 48 (48–51) 51 (48–51) 45 (37–46) 55 (53–57) 47 (43–55)
Male 2 2 2 4 6
MSM 2 2 2 4 6
Heterosexual (HTSX) 1 1 1 0 0
Intravenous drug user (IDU) 0 0 0 2a 0
Hepatitis C virus (HCV) infection 0 0 0 2b 0
Median CD4þ cell count at baseline (IQR) 762 (686–770) 726 (716–824) 821 (741–957) 829 (680–1124) 904 (868–1071)
Median CD4þ cell count at week 6 (IQR) 672 (663–683) 938 (784–993) 643 (589–1040) 819 (640–928) 956 (805–1053)
IQR: Interquartile range.
aFormer IDU.
bBoth HCV infections cured: 1 spontaneously (2009), 1 treated with sofobusvir/daclatasvir (2015).Increased frequencies of HIV-1-specific T cells
after iHIVARNA vaccination
At week 8, patients who had received the highest
iHIVARNA dose (group 5) showed a moderate increase
in T-cell responses spanning HTI sequence (IN) at week 8
whereas no changes were observed in responses against
the rest of the HIV-1 proteome (OUT) compare to
baseline (Fig. 3). In addition, the proportion of
responders receiving any dose of iHIVARNA (n¼ 15)
increased from 31% (n¼ 5) at week 0 to 80% (n¼ 12)
postvaccination. This increase was not observed in
patients receiving TriMix alone (n¼ 6) from 50%
(n¼ 3) to 67% (n¼ 4). The HIV-specific T-cell responses
were mainly directed against the following peptide pools:
p2 (Gag p17), p4 (Gag p24), p5 (Gag p15), p7 (RT) and
p8 (INT), in the IN-peptide pools, whereas in the HIV
OUT-peptide pools, the responses were mainly towards:
p1 (Gag), p2 (Pol), p4 (Pol), p6 (Env), p7 (Vif, Nef) and
p8 (Tat, Vpu, Vpr, Rev; data not shown).
Concerning the analysis of cell subsets, we only observed
statistically significant decreases between baseline and
week 8 (fourth weeks after the last immunization) inTable 2. Total adverse events classified by severity and relationship with
Variable Value Val
Grade 1 N
%
Severity Grade 2 N
%
Grade 3 N
%
All N
Definite relationship N
%
Probable relationship N
%
Casual relationship Possible relationship N
%
No related N
%
Unknown N
%
All Npercentages of CD8þ CD38þHLA-DRþ T cells and
CD8þ PD-1þ T cells in group 5 (data not shown).
Increased viral expression but stable proviral
reservoir after iHIVARNA vaccination
Neither TriMix alone or different doses of iHIVARNA
had an impact on proviral HIV-DNA in any of the studied
arms (Fig. 4a). However, there was a transient increase in
caHIV-RNA expression at higher doses of iHIVARNA
(arms 4 and 5) during weeks 4–6 [whereas this was not
observed with TriMix alone (groups 1 and 2) or with low
doses of iHIVARNA (group 3)], and subsequently
normalized at weeks 8 and 24 (Fig. 4b). Moreover, the
ratio of ca-HIV RNA at week 6 as compared with week-
4 levels was significantly higher in patients receiving any
dose of iHIVARNA (groups 3–5 merged) vs. patients
receiving TriMix alone (P¼ 0.0126). Finally, usVL also
significantly increased at weeks 6 and 8 (P< 0.05) in
groups 4 and 5 and returned to baseline values at week 24
(Fig. 4c). In fact, further analysis of these two groups,
showed a positive and significant correlation between the
increase of the elicited T-cell immune responses against
HTI sequence (IN) and the usVL at week 6 (P< 0.05).the vaccination.
I II III IV V All
3 4 1 9 2 19
75 57 20 82 40 59
1 3 3 2 3 12
25 43 60 18 60 38
0 0 1 0 0 1
0 0 20 0 0 3
4 7 5 11 5 32
2 0 0 0 0 2
50 0 0 0 0 6
0 0 0 0 0 0
0 0 0 0 0 0
1 4 3 6 0 14
75 57 60 55 0 44
1 3 2 5 5 16
75 43 40 45 100 50
0 0 0 0 0 0
0 0 0 0 0 0
4 7 5 11 5 32
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Fig. 3. Changes in the magnitude of total HIV-1-specific immune responses against IN and OUT peptide pools as measured
by ELISPOT (at week 0, 4, 6, 8 and 24). Results were considered positive if the number of SFC/106 cells in stimulated wells was
two-fold higher than that in unstimulated control wells, and if there were at least 50 SFC/106 cells after background subtraction.
Mean differences from baseline (Dþ/ SEM SFC/106 PBMC) are represented on the graphs.
2540 AIDS 2018, Vol 32 No 17No significant correlation was observed between T-cell
responses against the rest of the HIV-1 proteome (OUT)
and the usVL (See Supplementary Fig. S1, http://
links.lww.com/QAD/B364).
iHIVARNA vaccination does not shift gene
expression
We did not observe robust differentially expressed genes in
any of the group-wise comparisons, although gene set
analysis indicates some effect on pathways such as RNA
metabolism and host response to viruses, but with very low
significance levels (Fig. 5). There were no differentially
expressed genes in anyof the group-wise comparisons or in
the immunologic responders vs. nonresponders, based on
ELISPOTassays. Gene set analysis indicated some effect of
the vaccine on pathways such asRNAmetabolism and host
response to viruses. These were related to the presence of a
patient effect and an effect of the HIV reservoir size.
However, these pathways had very low levels of
significance (FDR >0.1), indicating that there was only
a modest effect on most pathways.Discussion
Recently, direct intranodal administration of naked
mRNA has been proposed as an alternative to the
immunogens used so far in HIV vaccination trials. As
compared with plasmid DNA and viral vectors, mRNA
has a better safety profile, can be easily obtained by
commercially available kits and stored at room tempera-
ture. Additionally, mRNA-mediated gene transfer occurs
in nondividing cells and offers the advantage of not being
restricted to a subject-specific human leukocyte antigen
(HLA) allele [27]. Promising preliminary results have
been reported in other infectious diseases and cancer with
mRNA vaccines. Indeed, an mRNA influenza vaccine
candidate has demonstrated similar efficacy to licensed
vaccines in animal models [14], a prophylactic mRNA-
based candidate vaccine against rabies was well toleratedFig. 4. (a) Impact of the highest doses of iHIVARNA (Groups 4 an
(Groups 1 and 2) or the different doses of iHIVARNA (Groups 3–5)
of iHIVARNA (Groups 4 and 5) in HIV-1 ultrasensitive plasma Rand induced boostable functional antibodies [17] and
direct administration of mRNA has entered clinical
testing in cancer [15,16,18,19]. To our knowledge, this is
the first in human clinical trial using direct intranodal
administration of naked mRNA as a therapeutic vaccine
against HIV-1 infection. We have shown that intranodal
injection of the iHIVARNAvaccine was feasible, safe and
well tolerated. No severe adverse events were observed
even with the highest dose of the vaccine, namely group 5
constituting a total of 1200mg of mRNA (900mg HTI
mRNA and 300mg TriMix mRNA). Therefore, this
dose has been selected for a currently ongoing phase II
clinical trial.
The vast majority (98%) of latent viruses in chronic HIV-
1-infected patients carry CTL escape mutations that
render infected cells insensitive to CTLs directed at
standard (canonical) epitopes [28]. It is likely that many of
the therapeutic vaccines currently under evaluation
expand preexisting clones, which are exhausted and
target escape variants. There is specific interest in
approaches that stimulate responses against novel,
nondominant epitopes [13,29,30]. Mothe et al. [13]
proposed a rational design for the selection of the HIV
antigens based on the viral targets of protective HIV-1
specific T-cell responses from three large cohorts of HIV-
infected individuals [13]. In addition, two other groups
have hypothesized that T-cell vaccines targeting the most
conserved regions of the HIV-1 proteome will induce
more efficient immune response than whole protein-
based T-cell vaccines [31,32]. Letourneau et al. [33]
designed the HIVconsv immunogen by assembling the 14
most conserved regions of the HIV-1 proteome into one
chimeric protein.When delivered in vaccines vectored by
MVA and chimpanzee adenovirus, these vaccines were
able to shift preexisting immune responses towards
conserved, vaccine-encoded regions of HIV in early-
treated HIV-infected individuals [29–33]. Our iHI-
VARNA candidate supports this strategy. The data
presented indicate that the vaccine was able to induce
moderate HIV-specific immune responses (increase ind 5) in HIV-1 cell-associated total DNA. (b) Impact of TriMix
in HIV-1 cell-associated RNA. (c) Impact of the highest doses
NA
mRNA therapeutic vaccine for HIV infection Leal et al. 2541
Fig. 4. (Continued).magnitude and breadth as well as increase in percentage of
responders) against overlapping HIV peptide pools,
which matched the HTI sequence (’IN’) whereas no
augmented responses were observed against peptide pools
covering HIV proteins not included in the HTI sequence
(’OUT’). However, the Phase I results are not conclusive
because of the limited number of patients included in
each group.The ELISPOTassay has been established for the direct ex-
vivo quantification of peptide-reactive T lymphocytes
from peripheral blood mononuclear cells (PBMC).
However, it is true that the predictive power of this
assay has been challenged because of the lack of efficacy of
some HIV vaccine trials despite the induction of robust
Elispot responses [34]. This finding and the emergence of
new techniques that have the potential advantage of
2542 AIDS 2018, Vol 32 No 17
Fig. 4. (Continued).simultaneously quantifying numerous parameters, raises
questions regarding the future role of IFN-g Elispot in
clinical trials of candidate vaccines. Nevertheless, the
IFN-g Elispot assay has been, unlike other techniques,
evaluated and validated in several proficiency panels and is
advantageous in cost-effectively detecting and mapping
T-cell responses [35]. All these benefits are particularly
important in a Phase I clinical trial where safety and
tolerability were the major end-points.
There is evidence that HIV-1 vaccines are by themselves
insufficient to fully harness the stimulatory potential of
dendritic cells. It has been suggested that targeting in-vivo
dendritic cells by co-stimulatory molecules improves the
effectiveness of the vaccines [20,36]. This type of strategy
has already been tested in humans with a vaccine co-
expressing immune activator molecules. A clinical trial
testing a recombinant fowl pox virus vector co-expressing
HIV1Gag/Pol and human interferon-g has been reported
[37,38]. In addition, Van Lint et al. [20] designed mRNAs
encoding a mixture of APC activationmolecules, referred
as TriMix. Dendritic cells modified in vitro or in vivowith
TriMix mRNA have been shown to be significantly more
immunogenic than unmodified dendritic cells [20,21].
The higher doses of iHIVARNA mRNA might have
increased HIV expression as a transient increment in
caHIV-RNA expression and usVL were observed. It is
likely to be triggered by activation of the immune system
through recognition of TLRs. However, the existence of
a direct and significant association between the elicited
HIV-1 immune response against epitopes included in the
vaccine (and not to the rest of the proteome) and the usVL
(1 or 2 weeks after the last dose) suggest that it could besecondary to an specific stimulus rather than to an
ambiguous and unspecific reaction because of the mere
addition of mRNA. Given the limited number of
patients, this association needs to be further explored in
the ongoing phase IIa clinical trial to be confirmed.
Using whole blood-derived transcriptome analyses, we
only observed modest effects on inflammatory pathways.
These effects were related to intrinsic differences in the
activity of inflammatory pathways between individual
patients, rather than to the effect of any of the vaccine
formulations. Therefore, the data suggest that any
immune activation induced by this vaccine is modest
and not detectable by comprehensive transcriptome
profiling of whole blood samples.
In conclusion, this phase I exploratory dose-escalating
trial showed that iHIVARNA vaccination was feasible,
harmless and well tolerated, was able to induce
moderate HIV-specific immune responses and tran-
siently increased caHIV-RNA expression and ultrasen-
sitive plasma viremia. These data support further
exploration of iHIVARNA in the currently ongoing
phase II clinical trial.Acknowledgements
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